To access the full text documents, please follow this link: http://hdl.handle.net/2445/101000

Molecular analysis of isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates recovered from Barcelona.
Coll, Pere; Aragón, Lina Marcela; Alcaide Fernández de Vega, Fernando; Espasa, Mateo; Garrigó, Montserrat; González Martín, Julián; Manterola, Jose M.; Orús, Pilar; Salvadó, Margarita
Universitat de Barcelona
We studied the presence of mutations in the whole katG gene and specific regions of the oxyR-ahpC and mabA-inhA regulatory region in 61 Mycobacterium tuberculosis isoniazid-resistant isolates. An 81-bp region of the rpoB gene was also sequenced in 17 rifampin-resistant strains. Alterations in the katG gene were detected in 55% of the isolates. Mutation in codon 315 was the most prevalent (32%). Strains showed a high level of resistance, and most maintained a substantial catalase-peroxidase activity. Three strains with an isoniazid MIC of ≥32 µg/ml lacked catalase-peroxidase activity. Two of them had deletions in the catalytic domain of the KatG protein. One strain with deletion and three strains with mutations in the C-terminal domain showed low-level resistance and conserved the catalase-peroxidase activity. Mutations in the mabA-inhA regulatory region were identified in 32% of the isolates. All had low-level resistance, and the vast majority conserved catalase-peroxidase activity. Seventeen percent of the isoniazid-resistant isolates had no detectable alterations at the studied loci. Resistance to rifampin was associated with mutations in the 81-bp of the rpoB gene in all cases. IS6110 analysis indicated that recent transmission contributed substantially to the emergence of isoniazid- resistant tuberculosis in Barcelona through short transmission chains. A rapid genotypic assay, including the 315-katG codon and the -15 nucleotide of the mabA-inhA regulatory region, may cover 62% of isoniazid- resistant strains in Barcelona. In contrast, the targeting of the 81-bp region of rpoB would detect all our rifampin-resistant isolates.
-Mycobacterium tuberculosis
-Tuberculosi
-Medicaments antituberculosos
-Resistència als medicaments
-Genètica molecular
-Mycobacterium tuberculosis
-Tuberculosis
-Antitubercular agents
-Drug resistance
-Molecular genetics
(c) Mary Ann Liebert, Inc., 2005
Article
Article - Published version
Mary Ann Liebert, Inc.
         

Show full item record

Related documents

Other documents of the same author

Mansfeld, M.; Skrahina, A.; Shepherd, L.; Schultze, A.; Panteleev, A. M.; Miller, R. F.; Miró Meda, José M.; Zeltina. I.; Tetradov, S.; Furrer, H.; Kirk, O.; Grzeszczuk, A.; Bolokadze, N.; Matteelli, A.; Post, F. A.; Lundgreen, J. D.; Mocroft, A.; Efsen, A. M. W.; Podlekareva, D. N.; González Martín, Julián; Tudó i Vilanova, Griselda; Alcaide Fernández de Vega, Fernando; TB:HIV study group in EuroCoord
Mansfeld, M.; Skrahina, A.; Shepherd, L.; Schultze, A.; Panteleev, A. M.; Miller, R. F.; Miró Meda, José M.; Zeltina. I.; Tetradov, S.; Furrer, H.; Kirk, O.; Grzeszczuk, A.; Bolokadze, N.; Matteelli, A.; Post, F. A.; Lundgreen, J. D.; Mocroft, A.; Efsen, A. M. W.; Podlekareva, D. N.; González Martín, Julián; Tudó i Vilanova, Griselda; Alcaide Fernández de Vega, Fernando; TB:HIV study group in EuroCoord
Mansfeld, M.; Skrahina, A.; Shepherd, L.; Schultze, A.; Panteleev, A. M.; Miller, R. F.; Miró Meda, José M.; Zeltina. I.; Tetradov, S.; Furrer, H.; Kirk, O.; Grzeszczuk, A.; Bolokadze, N.; Matteelli, A.; Post, F. A.; Lundgreen, J. D.; Mocroft, A.; Efsen, A. M. W.; Podlekareva, D. N.; González Martín, Julián; Tudó i Vilanova, Griselda; Alcaide Fernández de Vega, Fernando; TB:HIV study group in EuroCoord
Battestini, R.; Aragón, Lina Marcela; Armengol, J.; Biete Solà, Albert; Broggi, Moisès, 1908-2012; García, C.; Moreno, F. X.; Navarro, F.
Rubio, Marc; March, Francesca; Garrigó i Fullola, Montserrat; Moreno, Carmen; Español, Montserrat; Coll Figa, Pedro
 

Coordination

 

Supporters